Praxis reports positive seizure reduction results from vormatrigine trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/20/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. ACN
9. AZN
10. SPCX

Go back to Praxis reports positive seizure reduction results from vormatrigine trial

TD Cowen Reiterates Buy Rating on Praxis Precision Medicines Inc. (PRAX)

August 4, 2025 2:10 PM EDT

TD Cowen analyst Ritu Baral reiterated a Buy rating and $61.00 price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX).

The analyst comments "Our Take: We are highly encouraged by today's data which we believe bodes well for PBO-controlled POWER1 Ph2/3 vormatrigene data due by... More

Praxis Precision Medicines Inc. (PRAX) PT Raised to $33 at Wedbush

August 4, 2025 1:24 PM EDT

Wedbush analyst Laura Chico raised the price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX) to $33.00 (from $28.00) while maintaining a Underperform rating.

The analyst comments "Remain Underperform rated on PRAX, new $33 target. While the headline figure for seizure reduction with vormatrigine represented... More

Praxis Precision Medicines Inc. (PRAX) PT Raised to $155 at Guggenheim

August 4, 2025 12:58 PM EDT

Guggenheim analyst Yatin Suneja raised the price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX) to $155.00 (from $120.00) while maintaining a Buy rating.

The analyst comments "Key Message: In the open-label RADIANT study (n=37), vormatrigine demonstrated an impressive 56.3% reduction in monthly seizure frequency... More